Project Grant R56HL171144
Award Date
9/24/24
Completion Date
8/31/25
Dollars Obligated
$778K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $817,208 to the Broad Institute of MIT and Harvard to study the genetic basis and underlying mechanisms of heart failure. The award will leverage high-throughput functional genomic assays, including cell painting and Perturb-seq, to systematically link genetic risk loci associated with heart failure to specific molecular and cellular...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $144,989.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and test deep generative models using computed tomography (CT) images to predict acute respiratory distress syndrome (ARDS) progression and treatment responses. The project aims to create generative adversarial networks (GANs) that can synthesize CT images...
This Project Grant award of $671,544, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate a cardiac ultrasound radiomics-guided deep learning model for precision phenotyping and risk stratification of acute myocardial infarction (AMI) patients. The key products and services to be delivered under this award include: (1) benchmarking the radiomics-guided deep neural network model against conventional...
This Project Grant award of $194,400 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a multilevel implementation intervention to equitably prescribe evidence-based therapy for hospitalized heart failure patients. The key products or services to be delivered through this funding include: Assessing multilevel variation in equitable guideline-directed medical therapy (GDMT) prescribing during...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,543,226 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a randomized controlled trial assessing the effects of SGLT2 inhibitors on coronary flow reserve and epicardial adipose tissue among women living with HIV. The goal is to identify novel interventions to address the increased risk of myocardial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $321,363 to Nucleusrx, Inc. to develop and test a virtual care platform and remote intervention tool targeting post-acute care heart failure (HF) patients. The goal is to create a solution that enables healthcare providers to implement a safe discharge transition plan from hospital to home, while allowing rapid optimization of...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $774,972 provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the impact of changes in the healthcare market, such as hospital mergers and closures, on cardiovascular and cerebrovascular care and outcomes. The primary objectives are to: 1) Examine the effects of hospital mergers and acquisitions on the receipt of...
This Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, was awarded under the Cardiovascular Diseases Research program (CFDA 93.837) to develop clinical software to support quantitative analysis and interpretation of myocardial contrast echocardiography (MCE) data. Narnar, LLC received $757,197 to create software modules that enhance MCE's ability to identify coronary microvascular dysfunction (MVD). The software will average...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $708,266 to The General Hospital Corporation (Massachusetts General Hospital) to study the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The award aims to determine SALTE1's role in vascular aging and HFPEF, as well as the underlying mechanisms. The research will be conducted at Massachusetts...